Format

Send to

Choose Destination
Expert Rev Hematol. 2009 Oct;2(5):517-32. doi: 10.1586/ehm.09.47.

Adoptive T-cell therapy for B-cell malignancies.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. mhudecek@fhcrc.org

Abstract

The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.

PMID:
21083018
PMCID:
PMC3118544
DOI:
10.1586/ehm.09.47
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center